|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:CV_Therapeutics
gptkb:Corus_Pharma
gptkb:EpiTherapeutics
gptkb:Immunomedics
gptkb:Kite_Pharma
gptkb:Myogen
gptkb:Pharmasset
gptkb:Talon_Therapeutics
|
|
gptkbp:CEO
|
gptkb:Daniel_O’Day
|
|
gptkbp:city
|
gptkb:Foster_City
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
gptkb:hepatitis_C
gptkb:hepatitis_B
oncology
antiviral drugs
HIV/AIDS treatment
|
|
gptkbp:foundedBy
|
gptkb:Michael_L._Riordan
|
|
gptkbp:foundedYear
|
1987
|
|
gptkbp:headquartersLocation
|
gptkb:Foster_City,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:marketCap
|
over $80 billion (2024)
|
|
gptkbp:memberOf
|
gptkb:S&P_500
|
|
gptkbp:netIncome
|
$5.3 billion (2023)
|
|
gptkbp:notableEvent
|
acquired Immunomedics for Trodelvy
acquired Kite Pharma for CAR-T therapy
developed first FDA-approved COVID-19 treatment
faced criticism over drug pricing
launched Sovaldi for hepatitis C
major player in HIV/AIDS drug market
|
|
gptkbp:notableInvention
|
gptkb:remdesivir
gptkb:sofosbuvir
bictegravir
emtricitabine
ledipasvir
tenofovir
velpatasvir
|
|
gptkbp:notableProduct
|
gptkb:Biktarvy
gptkb:Harvoni
gptkb:Remdesivir
gptkb:Sovaldi
gptkb:Truvada
gptkb:Veklury
|
|
gptkbp:numberOfEmployees
|
over 17,000
over 17,000 (2023)
|
|
gptkbp:operatesIn
|
global
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:revenue
|
$27.1 billion (2023)
|
|
gptkbp:state
|
gptkb:California
|
|
gptkbp:stockSymbol
|
gptkb:GILD
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.gilead.com/
|
|
gptkbp:bfsParent
|
gptkb:Gordon_Earle_Moore
|
|
gptkbp:bfsLayer
|
4
|